Aventis Pharma (Pakistan) Limited

[Formerly Hoechst Marion Roussel (Pakistan) Limited] Annual Report 2000

Contents

Notice of Meeting
Company Information
Ten-Year Summary of Statistics
Directors' Report
Pattern of Shareholding
Auditors' Report
Balance Sheet
Profit and Loss Account
Statement of Changes in Equity
Cash Flow Statement
Notes to the Accounts

NOTICE OF MEETING

Notice is hereby given that the Thirty-third Annual General Meeting of the Company will be held on Monday, April 09, 2001 at 10:00 hours in the Conference Hall of the Overseas Investors Chamber of Commerce and Industry, Talpur Road, Karachi to transact the following business:

- 1. To confirm the minutes of the last Annual General Meeting.
- 2. To receive and adopt the Balance Sheet and Profit & Loss Account for the year ended December 31, 2000 together with the Directors' and Auditors' reports thereon.
- 3. To approve the dividend for the year @ Rs.3.50 per share, as recommended by the Directors.
- 4. To appoint Auditors for the year ending December 31, 2001 and to fix their remuneration. The retiring Auditors, M/s. A.F. Ferguson & Co., being eligible offer themselves for re-appointment.

By Order of the Board

M. Z. Moin Mohajir
Director/Secretary

Karachi, March 16, 2001

Notes:

- 1. The Share Transfer Books of the Company shall remain closed from March 27, 2001 to April 09, 2001 (both days inclusive) for the purpose of determining the dividend.
- 2. A member entitled to attend and vote at the above meeting may appoint a Proxy to attend and vote on his behalf. No person shall be appointed as Proxy who is not a member of the Company qualified to vote except that a Corporation being a member may appoint as Proxy a person who is not a member. The completed Proxy Form must be deposited at the Registered Office of the Company not less than 48 hours before the time for holding the meeting.
- 3. Shareholders whose shares are deposited with Central Depository Company (CDC) are requested to bring their Original National Identity Card and account number in CDC for verification.
- 4. For the convenience of our shareholders who wish to avail transport facility, company transport will be available at the Karachi Stock Exchange Building and will leave for Overseas Investors Chamber of Commerce and Industry at 9:30 a.m. sharp. After the Annual General Meeting, the company transport will take the shareholders back to the Karachi Stock Exchange Building.

COMPANY INFORMATION

Board of Directors Syed Babar Ali

M. Tariq Umar Pir Ali Gohar Syed Hyder Ali Chairman Managing Director (Alternate Asif Ali Gohar) Michel R. Lienard Hans D. Hausner M. Z. Moin Mohajir (Alternate Jacques Perez (Alternate A. R. Tahir)

Company Secretary

M.Z. Moin Mohajir

Auditors

A.F. Ferguson & Co.

Legal Advisors

Fatehali W. Vellani & Company

Azfar & Azfar Orr, Dignam & Co. Rizvi, Isa & Co.

Bankers

ABN AMRO Bank N.V.

Citibank, N.A.

Credit Agricole Indosuez Deutsche Bank AG Habib Bank Limited

Hongkong & Shanghai Banking Corporation Ltd.

Muslim Commercial Bank Ltd.

Societe Generale - The French & International Bank

Standard Chartered Bank

Standard Chartered Grindlays Bank Ltd.

Registered Office

Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi-74900.

Postal Address

P.O. Box No. 4962, Karachi - 74000.

Registrars & Share Transfer Office Ferguson Associates (Pvt.) Ltd. State Life Building No. l-A, I.I. Chundrigar Road, Karachi-74000.

TEN-YEAR SUMMARY OF STATISTICS

(Rupees in thousands)

(Rupees in thousands)	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
Operating assets	116,275	141,409	157,538	188,010	355,691	311,715	284,104	240,995	190,155	146,164
Capital work-in-progress	29,388	25,888	45,222	183,058	36,012	105,163	1,638	3,565	6,874	23,823
Net current & other assets	49,564	48,514	51,015	253,213	129,657	(16,737)	117,112	88,646	226,007	175,653
Total assets employed	195,227	215,811	253,775	624,281	521,360	400,141	402,854	333,206	423,036	345,640
Ordinary capital	57,873	69,448	69,448	69,448	69,448	69,448	69,448	69,448	69,448	69,448
Reserves	80,631	98,633	151,775	201,584	212,125	204,949	221,752	237,987	242,675	276,192
Redeemable capital	31,650	22,350	13,050	240,000	136,667	49,333	62,000	8,000	104,000	
Long term & deferred liabilit	25,073	25,380	19,502	113,249	103,120	76,411	49,654	17,771	6,913	
Total funds employed	195,227	215,811	253,775	624,281	521,360	400,141	402,854	333,206	423,036	345,640
Net turnover	1,112,096	1,272,943	1,308,682	1,532,542	1,960,288	1,422,957	1,409,552	1,420,712	1,624,284	1,800,607
Indenting commission	16,196	15,619	18,800	18,585	17,919	18,293	16,135	17,868		
Profit before taxation	77,526	80,898	82,182	72,063	40,170	32,743	61,808	62,285	70,348	136,664
% of net sales	7.00	6.40	6.30	4.70	2.00	2.30	4.40	4.40	4.30	7.60
% of average assets employ	48.70	39.40	35.00	16.40	7.00	7.10	15.40	16.90	18.60	35.60
Profit / (loss) after taxation	41,882	43,466	53,142	63,699	24,431	(7,176)	30,692	30,123	22,050	57,824
Cash dividend - amount		13,889		13,890	13,890		13,889	13,888	17,362	24,307
Cash dividend - %		20		20	20		20	20	25	35
Bonus issue - amount	11,575									
Bonus issue - %	20									

Earnings per share Rs. (based on profit before tax)	13.39	11.64	11.80	10.30	5.78	4.70	8.90	8.97	10.12	19.68
Number of permanent employees at year end	923	953	941	954	1,007	882	626	521	509	508

DIRECTORS' REPORT

We are pleased to present the Annual Report of your company for the year ended December 31, 2000.

Sales were 11.6% above last year, which was well above the Pakistan Pharmaceuticals Market growth of 6%. Profit before tax of Rs.136.6 million is a record for the company and it is 94% more than last year. This excellent achievement was due to the full benefits arising out of several restructuring, streamlining and cost saving actions taken in the last couple of years. This result was despite a number of negative factors which were beyond the control of your company's management. These included 1) continued stagnation of the economy with consequent impact on sales, 2) no price increase for 4 products including 2 of our largest products - Claforan® 1gm and Tarivid®, 3) price increase granted for other products from July 2000 only, 4) devaluation of Pak rupee by approximately 13% starting from July 2000 thereby neutralizing the benefits of the price increase, 5) increase in cost of electricity, petrol and travel, etc.

We launched two new products during the year - Targocid® (200mg and 400rag Injections) in June 2000 and Tavanic® (250mg and 500mg Tablets) in December 2000. These are antibiotics and the initial response to both the products was very positive and we expect them to develop quite well during the year 2001.

We again exported pharmaceutical products worth Rs.15 million to Thailand during the year and expect this business to grow.

Appropriat Profit for the	ions e year before taxation	(Rs.000) 136,664
Taxation:		
Current	- for the year	84,000
	- for prior years	1,753
Deferred	- for the year	(6,913)
		78,840
Profit after t	axation	57,824
Unappropria	ated profit brought forward	175
		57,999
Appropriation	ons:	
Proposed di	vi I	24,307
Transfer to 0	General Reserve	33,500
		57,807
Unappropria	ated profit carried forward	192
		========

Tax provision for current year is high due to timing and some permanent differences which have been accounted for in the tax computation.

In view of the excellent profit the Directors are pleased to recommend a dividend of 35% i.e. Rs.3.50 per share which, if approved, by the shareholders, will be the highest cash dividend in the history of the company.

Human Resource

The total number of permanent employees at the end of 2000 were 508, a further reduction of 1 as compared to the end of last year despite increase in sales and related operations.

Productivity based incentives introduced in the factory 2 years back resulted in further productivity improvement of over 6% this year as compared to 1999 which had already registered a productivity growth.

Information Technology

The 5 SAP modules which we use are now being upgraded and our Information Technology department

is one of the most advanced in the country. This, however, also means that we incur significant costs to maintain this modern tool and we need to spend more to extend the SAP system to all our branches.

Safety & Environment

Further training of concerned staff to maintain and even to enhance the level of quality standards of Environment, Health and Safety has been one of the company's achievements during the year.

Future Outlook

We have to once again repeat this year that the pharmaceutical industry continues to be depended on the Government in respect of pharmaceutical price increases and to be wary of the regular devaluation of Pak rupee. As mentioned above the restricted price increases granted after 3 years and 8 months towards the end of June 2000 were quickly neutralized by the devaluation of the Pak rupee immediately thereafter. Despite our best efforts to control costs and introduce innovative ideas, it is to be understood that there is a certain limit on such actions and factors like inflation and Pak rupee devaluation are realities on which we have no control.

Our policy of launching new products will continue this year also and together with the products launched last year we hope that new products will contribute significantly to our overall turnover.

The merger of Hoechst AG and Rhone-Poulenc Rorer SA Life Sciences into a new company Aventis SA has been completed in nearly all the countries of the world. In Pakistan we are still looking into the various aspects of the merger and shall revert back to you in this regard very soon.'

Directors

Mr. Michel Lienard and Mr. H.D. Hausner, have been nominated by Aventis Pharma Holding GmbH to fill the casual vacancies in the Board of Directors created due to the resignations of Mr. Pascal Soriot, who has taken over new responsibilities in the United States and Mr. F.X. Roger, who has left the Company. We would like to thank the outgoing members for their contribution to the Company during their tenure on the Board and welcome the new nominees.

Pattern of Shareholding

A statement of the pattern of shareholding.

Earning Per Share

The earning per share before tax is Rs.19.68, which is once again the best ever performance by your company.

Holding Company

The company is a subsidiary of Aventis Pharma Holding GmbH, which is incorporated in Germany.

Auditors

The present Auditors Messrs A.F. Ferguson & Company retire and, being eligible, offer themselves for reappointment.

Genera

We would like to thank all the employees, who have once again played a significant role in your company's good performance.

By order of the Board

SYED BABAR ALI

M. TARIQ UMAR

Karachi: 26th January, 2001

Chairman

Chief Executive

PATTERN OF SHAREHOLDING AS AT DECEMBER 31, 2000

NUMBER OF	SHAREHOLDING		TOTAL
SHAREHOLDERS	From	To	SHARES HELD
305	1	100	14,034
376	101	500	114,341
76	501	1000	57,627
72	1001	5000	135,803
6	5001	10000	46,404
1	10001	15000	10,651
3	15001	20000	54,877

3 20001 25000 71,74 1 25001 30000 29,83 1 30001 35000 31,23 1 45001 50000 50,00 1 50001 55000 51,44 2 55001 60000 113,88 1 200001 205000 204,00 1 340001 345000 341,70 1 465001 470000 465,50	322 222 000
1 30001 35000 31,22 1 45001 50000 50,00 1 50001 55000 51,4 2 55001 60000 113,89 1 200001 205000 204,00 1 340001 345000 341,70 1 465001 470000 465,51	222
1 45001 50000 50,00 1 50001 55000 51,4 2 55001 60000 113,80 1 200001 205000 204,00 1 340001 345000 341,70 1 465001 470000 465,50	000
1 50001 55000 51,4 2 55001 60000 113,8 1 200001 205000 204,0 1 340001 345000 341,7 1 465001 470000 465,5	
2 55001 60000 113,8 1 200001 205000 204,0 1 340001 345000 341,7 1 465001 470000 465,5	42
1 200001 205000 204,0 1 340001 345000 341,7 1 465001 470000 465,5	
1 340001 345000 341,70 1 465001 470000 465,5	96
1 465001 470000 465,5	199
	02
510001 515000 510.0	23
1 510001 515000 510,2	212
1 1160001 1165000 1,161,8	394
1 3475001 3480000 3,479,4	69
854 6,944,76	60

CATEGORIES OF SHAREHOLDERS	NUMBER	SHARES HELD	PERCENTAGE
Financial Institutions	5	143,691	2.07
Individuals	822	1,353,588	19.50
Insurance Companies	3	1,385,842	19.96
Investment Companies	6	475,951	6.85
Joint-Stock Companies	11	3,541,257	50.99
Modaraba Companies	2	16,300	0.23
Charitable Trusts	1	82	
Others	4	28,049	0.40
	854	6,944,760	100.00

AUDITORS' REPORT AND FINANCIAL STATEMENTS

We have audited the annexed balance sheet of Aventis Pharma (Pakistan) Limited [formerly Hoechst Marion Roussel (Pakistan) Limited] as at December 31, 2000 and the related profit and loss account, statement of changes in equity and cash flow statement together with the notes forming part thereof, for the year then ended and we state that we have obtained all the information and explanations which, to the best of our knowledge and belief, were necessary for the purposes of our audit.

It is the responsibility of the Company's management to establish and maintain a system of internal control, and prepare and present the above said statements in conformity with the approved accounting standards and the requirements of the Companies Ordinance, 1984. Our responsibility is to express an opinion on these statements based on our audit.

We conducted our audit in accordance with the auditing standards as applicable in Pakistan. These standards require that we plan and perform the audit to obtain reasonable assurance about whether the above said statements are free of any material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the above said statements. An audit also includes assessing the accounting policies and significant estimates made by management, as well as, evaluating the overall presentation of the above said statements. We believe that our audit provides a reasonable basis for our opinion and, after due verification, we report that:

- (a) in our opinion, proper books of account have been kept by the Company as required by the Companies Ordinance, 1984;
- (b) in our opinion:
- (i) the balance sheet and profit and loss account together with the notes thereon have been drawn up in conformity with the Companies Ordinance, 1984 and are in agreement with the books of account and are further in accordance with accounting policies consistently applied;
- (ii) the expenditure incurred during the year was for the purpose of the Company's business; and
- (iii) the business conducted, investments made and the expenditure incurred during the year

were in accordance with the objects of the Company;

(c) in our opinion and to the best of our information and according to the explanations given to us, the balance sheet, profit and loss account, statement of changes in equity and cash flow statement together with the notes forming part thereof conform with the approved accounting standards as applicable in Pakistan, and, give the information required by the Companies Ordinance, 1984, in the manner so required, and respectively give a true and fair view of the state of the Company's affairs as at December 31, 2000 and of the profit, changes in equity and its cash flows for the year then ended; and

(d) in our opinion Zakat deductible at source under the Zakat and Ushr Ordinance, 1980 (XVIII of 1980), was deducted by the Company and deposited in the Central Zakat Fund established under Section 7 of that Ordinance.

A.F. Ferguson & Co. Chartered Accountants

Karachi: February 8, 2001

BALANCE SHEET AS AT DECEMBER 31, 2000

SHARE CAPITAL AND RESERVES	Note	2000 (Rupees in th	1999 ousands)
Authorised Capital 10,000,000 Ordinary shares of Rs. 10 each		100,000	100,000
Issued, subscribed and paid - up .capital	3	69,448	69,448
Revenue reserve		276,000	242,500
Unappropriated profit		192	175
		345,640	312,123
REDEEMABLE CAPITAL	4		104,000
DEFERRED TAXATION	5		6,913
CURRENT LIABILITIES			
Current maturity of redeemable capital	4	104,000	4,000
Short - term running finances utilized			
under mark - up arrangements	6	100,450	158,570
Creditors, accrued and other liabilities	7	286,370	334,122
Proposed dividend		24,307	17~362
		515,127	514,054
CONTINGENCIES AND COMMITMENTS	8		
		860,767	937,090
TANGIBLE FIXED ASSETS			
Operating assets	9	146,164	190,155
Capital work-in-progress	10	23,823	6,874
		169,987	197,029
LONG - TERM DEPOSITS		2,103	550
LONG -TERM LOANS AND ADVANCES	11	3,524	2,006
CURRENT ASSETS		- ,-	,
Stores and spares	12	23,784	24,352
Stock-in-trade	13	365,061	413,464
Trade debts	14	221,702	75,831
Loans and advances	15	4,218	4,576
Deposits and short-term prepayments	16	30,094	139,685
Taxation	-	22,193	69,977
		,	

Other receivables	17	13,521	8,093
Bank and cash balances	18	4,580	1,527
		685,153	737,505
		860,767	937,090
		=======================================	

The annexed notes form an integral part of these accounts.

SYED BABAR ALI

Chairman

M. TARIQ UMAR

Chief Executive

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED DECEMBER 31, 2000

	Note	2000	1999
		(Rupees in th	nousands)
Net Sales	19	1,800,607	1,624,284
Cost of Goods Sold	20	1,218,270	1,149,727
Trading profit			474,557
Administration and Selling expenses	21	409,889	
Operating profit		172,448	
Other income	22		32,344
		193,163	
Financial charges	23	37,784	33,184
Other charges	24	18,715	12,137
		56,499	45,321
Profit before taxation		136,664	70,348
Taxation	25	78,840	48,298
Profit after taxation		57,824	
Profit brought forward		175	487
Profit available for appropriation Appropriations:		57,999	
Transfer to revenue reserve Proposed dividend Rs. 3.50 per share		33,500	5,000
(1999: Rs. 2.50 per share)		24,307	
		57,807	*
Unappropriated profit carried forward		192	175
Familian and shore Desir and diluted	26	Rupees	Rupees
Earnings per share - Basic and diluted	26	8.33	3.18

The annexed notes form an integral part of these accounts.

SYED BABAR ALI

Chairman

M. TARIQ UMAR

Chief Executive

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED DECEMBER 31, 2000

Issued,	Revenue	Unappropriated	Total
subscribed	reserve	profit	
paid-up share			
capital			
	(Rupe	es in thousands)	

Balance at December 31, 1998	69,448	237,500	487	307,435
Profit for the year			22,050	22,050
Dividends			(17,362)	(17,362)
Transfer to g -		5,000	(5,000)	
Balance at December 31, 1999	69,448	242,500	175	312,123
Profit for the year			57,824	57,824
Dividends			(24,307)	(24,307)
Transfer to general reserve		33,500	(33,500)	
Balance at December 31, 2000	69,448	276,000	192	345,640

The annexed notes form an integral part of these accounts.

SYED BABAR ALI

M. TARIQ UMAR

Chairman

Chief Executive

CASH FLOW STATEMENT FOR THE YEAR ENDED DECEMBER 31, 2000

	Note	2000	1999
		(Rupees in th	ousands)
Cash flows from operating activities			
Cash generated from operations	27	186,366	15,034
Financial charges paid		(37,046)	(39,551)
Tax paid		(37,969)	(85,299)
Long-term deposits and prepayments (net)		(1,553)	(100)
Long-term loans and advances (net)		(1,518)	(878)
Net cash inflow/(out flow) from operating activities		108,280	(110,794)
Cash flows from investing activities			
Fixed capital expenditure			(17,076)
Sale proceeds of fixed assets		2,256	3,940
Interest received		3,212	874
Net cash (out flow) from investing activities		(25,804)	(12,262)
Cash flows from financing activities			
Proceeds from redeemable capital			100,000
Repayments of redeemable capital		(4,000)	(24,000)
Repayments of long-term loan			(24,878)
Dividends paid		(17,303)	(13,909)
Net cash (outflow)/inflow from financing activities		(21,303)	37,213
Net increase/(decrease) in cash and cash equivalents		61,1 73	(85,843)
Cash and cash equivalents at beginning of the year		(157,043)	(71,200)
Cash and cash equivalents at end of the year	28	(95,870)	(157,043)

The annexed notes form an integral part of these accounts.

SYED BABAR ALI

M. TARIQ UMAR

Chairman

Chief Executive

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED DECEMBER 31, 20001

1. LEGAL STATUS AND NATURE OF BUSINESS

The Company is incorporated in Pakistan and is listed on Karachi, Lahore and Islamabad Stock Exchanges. It is engaged in the manufacturing and selling of pharmaceutical products.

Effective November 27, 2000, the name of the Company has been changed to Aventis Pharma (Pakistan) Limited.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis for preparation

These accounts have been prepared in accordance with the requirements of the Companies Ordinance, 1984 and International Accounting Standards as applicable in Pakistan.

2.2 Accounting convention

These accounts have been prepared under the historical cost convention.

2.3 Retirement benefits

The Company operates approved and funded defined benefit pension scheme for all its permanent senior management staff, excluding expatriates. The scheme provides pension based on the employee's average basic salary during the last three year of service. Pensions are payable for life and thereafter to surviving spouses and/or dependent children. The Company also operates approved and funded defined gratuity schemes for all its permanent employees, excluding expatriates. Gratuity is based on the last drawn basic salary.

The "Projected Unit Credit" Actuarial Cost Method, in conjunction with the following significant assumptions is used for the valuation:

Discount rate 12% pa Expected rate of return on plan assets 12% pa Expected rate of salary increases 12% pa

The Company's policy with regard to actuarial gains/losses is to follow minimum recommended approach under IAS 19 (revised 1998) Employee Benefits.

The Company also operates an approved defined contribution provident fund for all its employees, excluding expatriates. Equal monthly contributions are made, both by the Company and the employees to the Fund at the rate of 8.33% and 10% of basic salary in respect of employees having service upto ten years and above ten years' respectively.

2.4 Taxation

Current

Provision for current taxation is based on taxable income at the current rate of taxation after taking into account tax credits available, if any.

Deferred

The Company accounts for deferred taxation using the liability method on all major timing differences. However, as a matter of prudence, the Company does not account for net deferred tax debit balance. As at December 31,2000 deferred tax debit balance not recognised in the accounts amounted to Rs. 25.583 million.

2.5 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less accumulated depreciation/amortization except for freehold land and capital work-in-progress which are stated at cost. Exchange differences and cost of borrowings, during construction period, in respect of loans obtained for a specific project, net of return on deposit account out of the proceeds of such loans are included in cost of respective assets. Depreciation charge is based on straight line method whereby the cost of an asset is written-off over its estimated useful life. Depreciation on additions is charged from the month in which asset is put to use and on disposals upto the month the asset is in use. Additional depreciation at the rate of fifty percent of the normal rate is charged on such machinery which is operated on double shift during the year. Cost of leasehold land is amortized equally over the period of lease.

Gains or losses on disposal/retirement of assets are taken to profit and loss account. Maintenance and normal repairs are charged to income as and when incurred. Major renewals and improvements are capitalised and the assets so replaced, if any, are retired.

2.6 Stores and spares

These are valued at moving average cost, computed at monthly rests except items in transit which are valued at cost comprising invoice value plus other charges paid thereon.

2.7 Stock-in-trade

These are valued at the lower of cost and net realisable value except for goods-in-transit which are stated at invoice value plus other charges paid thereon. Cost signifies standard costs adjusted by variances. Cost in relation to work-in-process and finished goods represents direct cost of materials, direct wages and appropriate manufacturing overheads. Net realisable value signifies the estimated selling price in the ordinary course of business less costs necessarily to be incurred to make the

sale.

2.8 Foreign currencies

Assets and liabilities in foreign currencies are translated into Pak rupees at the rates of exchange prevailing on the balance sheet date except where forward exchange contracts have been entered into for repayment of liabilities in which case the rate contracted for is used.

Exchange differences in respect of foreign currency loans obtained for acquisition of fixed assets are incorporated in the cost of the relevant assets. Exchange differences capitalized include loss or gain on the repayments and year-end translation of foreign currency loans and translation of deposits with the banks out of the proceeds of these loans arising during the period of project.

All other exchange gains and losses are included in income currently.

2.9 Revenue recognition

Sales of products and services are recorded on despatch of products or performance of services.

	2000 (Rupees in th	1999 housands)
3. ISSUED, SUBSCRIBED AND PAID-UP CAPITAL		
2,757,783 ordinary shares of Rs 10 each fully paid in cash	27,578	27,578
827,500 ordinary shares of Rs 10 each		
issued as fully paid for consideration other than cash	8.275	8.275
outer than cash	0,273	0,273
3,359,477 ordinary shares of Rs 10 each		
issued as fully paid bonus shares	33,595	33,595
6,944,760	69,448	69,448

At December 31, 2000 3,479,469 (1999: 3,479,469) ordinary shares of the Company were held by Aventis Pharma Holding GmbH, Germany.

4. REDEEMABLE CAPITAL - Secured (Non-participatory)

Long-term finances from commercial banks under mark-up arrangements:

	Sale	Purchase	Prompt		2000	1999
	Price	Price	Price Payment Rebate		(Rupees in thousands)	
Finance 1	20,000	40,925	8,560	4.10	4,000	8,000
Finance 2	50,000	103,125	43,938	4.20	50,000	50,000
Finance 3	50,000	76,285	16,978	4.30	50,000	50,000
					104,000	108,000
Classified as:				=		========
Long term						104,000
Short term					104,000	4,000
				=	104,000	108,000

- 4.1 Mark-up is chargeable on outstanding balance at the rate of 13% per annum and is repayable by August 1, 2001 in six half yearly equal installments. The facility is secured by first mortgage of the Company's present and future immovable properties including land at Korangi, Karachi.
- 4.2 Mark-up is chargeable on outstanding balance at the rate of 12.25% per annum and is repayable by June 27, 2001 in lumpsum. The facility is secured by way of hypothecation over the Company's stocks and book debts.
- 4.3 Mark-up is chargeable on outstanding balance at the rate of 12.25% per annum and is repayable by June 28, 2001 in lumpsum. The facility is secured by way of hypothecation over the Company's

stocks and book debts.

	2000	1999
	(Rupees in	thousands)
5. DEFERRED TAXATION		
This is composed of the following:		
Defermed liability origins due to accelerated		
Deferred liability arising due to accelerated		
depreciation allowances and other timing		
differences	6,913	10,734

Deferred debit arising in respect of provisions

-- 6,913

(3,821)

(6,913)

2000

6. SHORT-TERM RUNNING FINANCES UTILISED UNDER MARK-UP ARRANGEMENTS - Secured

100,450 158,570

1000

- 6.1 The facilities for short-term running finances available from banks under mark-up arrangements amount to Rs.700.30 million (1999: Rs. 621.30 million). The facilities expire on various dates by June 30, 2001. The rates of mark-up range from Re 0.3425 to Re 0.3836 (1999: Re 0.3562 to Re 0.4110) per Rs.1,000 per day. These arrangements are secured by way of hypothecation of the Company's stocks and book debts ranking pari-passu.
- 6.2 Out of the facilities of Rs.1,347.34 million (1999:Rs.1,309.29 million) for opening letters of credit, guarantees, bill discounting and export refinance, the amount unutilised at December 31, 2000 was Rs. 1,302.99 million (1999: Rs. 767.08 million).

	2000	1999
	(Rupees in th	ousands)
7. CREDITORS, ACCRUED AND OTHER /LIABILITIES		
Trade creditors	112,791	179,479
Bills payable	1,992	21,730
Accrued liabilities	145,557	114,671
Retirement benefits - note 7.1	476	
Short-term compensated absences	4,708	4,147
Security deposits - non-interest bearing	282	
Accrued mark-up on secured		
- redeemable capital	271	331
- short-term running finances	3,354	2,556
Excise duty	804	804
Sales tax		12
Royalty	2,860	4,201
Workers' Profits Participation Fund - note 7.2	7,515	3,845
Workers' Welfare Fund	5,325	1,970
Unclaimed dividends	435	376
	286,370	334,122

Amounts due to associated undertakings at year end aggregated Rs. 97.514 million (1999: Rs. 207.97 million).

7.1 Retirement Benefits

	Pension		Executive Gratuity		Non-Executive Gratuity		
	fund		fund		fund		
	2000	1999	2000	1999	2000	1999	
			(Rupees in thousands)				
Present value of defined benefit obligation	63,024	50,206	56,407	41,900	11.46	10,749	
Fair value of plan assets	(55,597)	(47,714)	(45,435)	(39,844)	(9,847)	(9,316)	
Funded status	7,427	2,492	10,972	2,056	1,610	1,433	
Unrecognised Actuarial gains / (losses)	(7,427)	(2,492)	(10,~72.)	(2,056)	(1,134)	(1,433)	

Net liability in balance sheet		 	 476	
	=======================================	 	 	=======
Opening net liability		 	 	
Total cost for the year	2,160	 3,902	 1,341	
Contribution paid by Company	(2,716)	 (4,552)	 (775	
Excess contribution accounted				
for in actuarial gains/(losses)	556	 650	 	
Closing net liability			 476	
-	===========	 	 	

	2000 (Rupees in th	1999
7.2 Workers' Profits Participation Fund	(Rupees in in	ousunus)
Balance at the beginning of the year	3,845	3,582
Allocation for the year	7,492	3,845
Prior year adjustment		(30)
	11,337	7,397
Interest on funds utilised in Company's business	516	393
Less: Amounts paid to the trustees of the fund	516	594
Deposited with the Government	3,822	3,351
	4,338	3,945
Balance at the end of the year	7,515	3,845

8. CONTINGENCIES AND COMMITMENTS

8.1 Contingent liabilities

- a) Guarantees to banks for repayment of loans given by the banks to certain employees of the Company amounted to Rs. 0.043 million (1999: Rs. 0.286 million).
- b) Bank guarantees aggregating Rs. 27.37 million as at December 31, 2000 (1999: Rs. 31.014 million) have been given to the Collector of Customs in respect of exemption of levies on import of specified pharmaceutical materials subject to consumption of such raw materials within the specified period.

8.2 Commitments

- a) Commitments in respect of capital expenditure contracted for as at December 31, 2000 amounted to Rs. 2.76 million (1 999: Rs. 1.38 million).
- b) Commitments in respect of forward exchange contracts as at December 31, 2000 amounted to Rs. 120.797 million (1999: Rs. 228.94 million).
- c) Commitments for rentals under operating lease agreements in respect of vehicles as at December 31, 2000 amounted to Rs. 7.6 million (1999: Rs. 5.1 million) payable over the next four years as follows:

2001	3,470
2002	2,135
2003	1,467
2004	590
	7,662

9. OPERATING ASSETS

9.1 The following is a statement of the operating assets:

Cost as	Additions/	Cost as	Accumulated	Depreciation	Accumulated	Net book	Annual
at January	(disposals)/	at December	depreciation	charge for	depreciation	value at	rate of
12,000	(W/offs)*	31, 2000	at January	the year/	at December	December	depreciation

				12,000	(disposals)/ (w/offs)* pees in thousan	31, 2000	31, 2000	%
				(Kuj	ices in thousan	ius)		
Leasehold land (note 9.3)	480		480	83	6	89	391	1.23
Freehold land	8,201		8,201				8,201	
Building on leasehold land	87,826		87,826	3,962	33,698	54,128	33,698	5
Building on freehold land	1,247		1,247	78	62	140	1,107	5
Plant and machinery	353,928	8,271	362,199	232,955	43,536	276,491	85,708	10
Furniture and fixtures	5,541	78	5,619	4,307	285	4,592	1,027	10
Vehicles	13,266	186 (3,115)	10,337	8,688	1,658 (2,336)	8,010	2,327	20
Factory and office equipment	57,833	5,788 (586) (2,154)*	60,881	41,890	7,973 (586) (2,101)*	47,176	13,705	7 to 33
	528,322	14,323 (3,701) (2,154)*	536,790	338,167	57,482 (2,922) (2,101)*	3	 390,626 146,	164
1999	525,252	13,767 (6,002) (4,695)*	528,322	284,257	61,290 (3,432) (3,948)*	338,167	190,155	

2000

1999

^{9.2} The plant and machinery was operated on a double shift basis during the year and accordingly additional depreciation at the rate of fifty percent of the normal annual depreciation has been charged on such machinery. The depreciation charge for the year has been allocated as follows:

	2000	1777	
	(Rupees in thousands		
Cost of goods sold - note 20	48,652	49,530	
Administration and selling expenses - note 21	8,830	11,760	
	57,482	61,290	
	==========		

9.3 The Company has granted to Aventis Crop Science Pakistan (Private) Limited [formerly AgrEvo Pakistan (Private) Limited], Karachi, associated undertaking, two exclusive licences for the use of the land for the period of 20 years commencing from 12th April, 1997 and 1st October, 1997, at licence fees. The licence fees for each of the first three years of the terms are Rs.2.60 million and Rs.0.82 million. Thereafter the licence fees shall be enhanced every year on the anniversaries of the agreements on the basis of the rate of inflation in Pakistan calculated on a twelve months moving average as defined by Government of Pakistan in the official Consumer Price Index most recently published prior to the relevant anniversary of the agreement. The licence fees are effective from January 1, 1997 and October 1, 1997.

9.4 The following assets were disposed off through negotiations/company policy during the year:

Description	Cost	Accumulated	Book	Sale	Sold to	
		Depreciation	Value	Proceeds		
(Rupees in thousands)						

Vehicles	57	25	32	32 Mr. Syed Habib Akbar (Ex-employee) H. No. B-14 Block 'S' North Nazimabad Karachi
	25	14	11	330 M/s. Sunrays Transport Co. D-104, AI Madina View Gulshan-e-lqbal, Karachi
	670	318	352	251 Mr. Zahir Shah (Ex-employee) Mohallah Mughal Khel Village & P.O Adezai Tehsil & District Peshawar
	25	15	10	337 Mr. Syed Shujjaullah Farooq Road, New Sabzi Mandi, Multan
	265	181	84	211 - do -
	70	48	22	55 Mr. Farid Khan (Ex-employee) Muslimabad No.3, (Guldara) Kakshal, Peshawar City
	202	202		80 Mr. Ahmed Jalil Ansari (Ex-employee) H. No. 1-E 16/2, Nazimabad, Karachi
	150	100	50	78 Mr. Khalid Aijaz H. No. 5/145 Shah Faisal Colony, Karachi
	225	150	75	127 - do -
	1,426	1,283	143	650 Mr. Ashraf Saeed H. No. 160-C, Block 3, P.E.C.H.S., Karachi
	3,115	2,336	779	2,151
Factory & Office Equipment				
Items having book value less than Rs. 5,000 each	586	586		105
	3,701	2,922	779	2,256
Old redundant items scraped				
Items having book value more than Rs. 5,000 each	80	44	36	
Items having book value less than Rs. 5,000 each	2,074	2,057	17	
	2,154	2,101	53	

2000 1999 (Rupees in thousands)

10. CAPITAL WORK-IN-PROGRESS

23,772 6,874 51 --23,823 6,874

11. LONG-TERM LOANS AND ADVANCES

- Considered Good		
Due from Executives	2,732	1,124
Less: Receivable within one year - note 15	759	300
	1,973	824
Due from Employees	2,754	2,217
Less: Receivable within one year - note 15	1,203	1,035
	1,551	1,182
	3,524	2,006
Outstanding for periods	=======================================	
- less than three years	3,510	2,006
- three years and more	14	
	3,524	2,006
	=======================================	

11.1 Loans to Executives are for the purpose of purchase of motor cars and are repayable within five years in equal monthly installments.

years in equal monthly installments.	rears and are repayable w	itiiiii iive
	2000	1999
	(Rupees in th	ousands)
11.2 The maximum aggregate amount due at the end of any month during the year from:		
Executives	2,629	1,392
12. STORES AND SPARES		
Stores	6,593	8,083
Spares		16,777
	24,268	24.860
Less: Provision for obsolescence	484	
		24,352
13. STOCK-IN-TRADE		
Raw and packing material and auxiliaries	198,799	197,803
Work-in-process	19,893	29,841
Finished goods	152,549	191,970
	371,241	419,614
Less: Provision for deterioration in stock	6,180	6.150
		413,464
14. TRADE DEBTS Considered good		
Unsecured	10.440	15.005
Associated undertakings - note 14.1		15,885
Others	208,254	59,946
	221,702	75,831

17,971 11,579 17,971 11,579

Considered doubtful Less: Provision thereagainst

	221,702	75,831
14.1 Due from associated undertakings: Ali Gohar & Company (Private) Limited	10,577	13,942
All Gohar Pharmaceuticals (Private) Limited	499	942
Aventis Pharma Limited, Thailand	2,468	1,001
	13,544	15,885
Less: Considered doubtful	96	
	13,448	15,885
The maximum aggregate amount due at the	=============	
end of any month during the year	15,939 =========	18,826
15. LOANS AND ADVANCES - Considered good		
Loans due from - Executives - note 11	759	300
- Employees - note 11	1,203	1,035
Advances against reimbursable expenses	400	• • •
to - Executives	689	268
- Employees	811	636
Advances to contractors and suppliers	756 	2,337
	4,218 =========	4,576
15.1 The maximum aggregate amount due at the end of		
any month during the year from: Chief Executive	441	225
Cnier Executive	441 ============	235 =====
Directors	32	186
Executives	1,597	1,288
16. DEPOSITS AND SHORT-TERM PREPAYMENTS		
Deposits - trade	5,714	3,654
- cash margins on letters of credit	18,710	132,335
Short-term prepayments	5,670	3,696
	30,094	139,685
17. OTHER RECEIVABLES - Considered good		
Due from associated undertakings - note 17.1	2,617	1,271
Commission	144	101
Due from outside party on account of services rendered	4,639	2,180
Insurance claims	2,874	27 4.51.4
Others	3,247	4,514
	13,521	8,093
17.1 Due from associated undertakings:		
Aventis Crop Science Pakistan (Private) Limited	184	553
HMR Interphar, France	650	
Rhone Poulenc Rorer Pakistan (Private) Limited	1,035	
Aventis Pharma, Deutschland, GmbH	551	659
Aventis Pharma International, France Hoechst Marion Roussel, Inc.	197	59
Troccust interior rousser, file.		

	2,617	1,271
The maximum aggregate amount due at the		
end of any month during the year	3,927	23,791
18. BANK AND CASH BALANCES		
Balance with banks - current accounts -note 18.1	510	
Cash in hand	4,070	1,302
		1,527
18.1 Included therein is an amount of Rs. 0.282 million (1999: Nil)	=======================================	
relating to suppliers' deposits.		
19. NET SALES Sales	1 872 340	1,677,798
Commission and discount to customers		(53,514)
Commission and discount to customers	(/1,/42)	
Net sales	1,800,607	1,624,284
20. COST OF GOODS SOLD		
Raw, auxiliary and packing material consumed:		
Opening stock	197,803	
Purchases	825,670	
Closing stock	(198,799)	(197,803)
	824,674	
Stores, spares and supplies	3,167	3,766
Salaries, wages and benefits - note 21.1 Fuel and power	74,835 25,010	53,801 24,258
Rent, rates and taxes	2,344	2,397
Insurance	2,156	2,273
Repairs and maintenance	14,545	18,000
Depreciation	48,652	49,530
Other expenses	17,445	13,197
Services rendered to outside party	(17,098)	. , ,
Opening stock of work-in-process	29,841	19,843
Closing stock of work-in-process	(19,893)	(29,841)
Cost of goods manufactured	1,005,678	1,019,410
Opening stock of finished goods	191,970	148,106
Finished goods purchased	201,321	200,916
Shown under administration and selling expenses: Cost of samples issued	(28,180)	(26,885)
Provision for deterioration in stock	30	150
Closing stock of finished goods	(152,549)	(191,970)
	1,218,270	1,149,727
21. ADMINISTRATION AND SELLING EXPENSES		
Salaries, wages and benefits - note 21.1	150,736	124,572
Fuel and power	5,295	6,687
Rent, rates and taxes	4,962	5,397
Insurance Pennirs, maintenance and supplies	3,179	2,141
Repairs, maintenance and supplies Depreciation	9,003 8,830	33,706 11,760
Travelling and conveyance	59,292	49,462
Communication	10,440	10,892
Advertising, samples and sales promotion	112,037	114,126
Software licence/maintenance fee	10,417	1,045
Royalty to associated undertaking	2,893	4,402
Other receivables written off		1,500

Provision for bad debts	6,393	7,315
Bad debts written off directly		215
Other expenses	27,573	19,962
	411,050	393,182
Recovery of service charges from outside party	(1,161)	(1,950)
	400,000	201.222
	409,889	391,232

21.1 Salaries, wages and benefits include the followings in respect of retirement benefits:

]	Non-Executive	e Gratuity		
	Pension f	fund	Executive Gra	tuity fund	fund		Total	I
	2000	1999	2000	1999	2000	1999	2000	1999
-				(Rupees in	thousands)			
Current service cost	2,158	1,456	3,446	2,644	680	522	6,284	4,622
Interest cost	3,273	2,393	4,828	3,986	1,262	1,026	9,363	7,405
Expected return on plan assets	(2,491)	(1,421)	(4,372)	(3,303)	(627)	(44)	(7,490)	(4,768)
Amortization of actuarial (gain)/loss					26		26	
Recognition of transitional obligation		9,280		7,391		8,542		25,213
Total cost	2,940	11,708	3,902	10,718	1,341	10,046	8,183	32,472
Expected employees' contribution	(780)	(588)					(780)	(588)
Net cost to Company	2,160	11,120	3,902	10,718	1,341	10,046	7,403	31,884

In addition to above, Rs 5.930 million (1999: 4.782 million) have been charged in respect of Company's contribution towards provident fund.

	2000	1999
	(Rupees in t	housands)
22. OTHER INCOME		
Interest from - associated undertakings	2,529	620
- others	464	480
Gain on sale of fixed assets	1,477	1,370
Sale of scrap	643	723
Exchange gains - net	2,471	
Licence fees from associated undertaking - note 9.3	4,227	4,104
Liabilities written back	1,158	23,239
Insurance claims	5,456	83
Others	2,290	1,725
	20,715	32,344
	=======================================	=======
23. FINANCIAL CHARGES		
Interest on - long-term loan		421
- workers' profits participation fund	516	393
Mark-up on - redeemable capital	13,055	2,052
- short-term running finances	14,444	15,108
- short-term loans	6,327	8,992
Exchange losses		1,319
Exchange risk cover fee		724
Bank charges	3,442	4,175
	37,784	The state of the s
24. OTHER CHARGES		
	2.290	1.061
Auditors' remuneration - note 24.2	2,289	1,061
Workers' Profits Participation Fund - current year	7,492	3,845
- prior year	2 216	(30)
Workers' Welfare Fund - current year	3,316	1,970
- prior year Fixed assets written-off - note 9.4	445	(85)
rixed assets written-off - note 9.4	53	747

Contribution for research and development fund	1,400	765
Legal & consultancy charges	2,299	1,692
Donations - note 24.1	133	161
Others	1,288	2,011
	18,715	12,137
	============	

24.1 Donation of Rs.30 thousand was given to World Wide Fund for Nature - Pakistan (Ferozepur Road, Lahore). Syed Babar All, the Chairman of the Board, Mr. Tariq Umar, the Chief Executive of the Company and Mr. M.Z. Moin Mohajir, Director and Company Secretary are the members of the Fund.

	2000	1999
	(Rupees in th	ousands)
24.2 AUDITORS' REMUNERATION		
Audit fee	300	275
Tax advisory services	984	500
Audit of provident, pension and gratuity funds	48	72
Special certifications	910	179
Out-of-pocket expenses	47	35
	2,289	1,061
	=======================================	=======
25. TAXATION		
Current - for the year	84,000	42,010
- for prior years	1,753	17,146
Deferred	(6,913)	(10,858)
	78,840	48,298

25.1 The Income Tax Officer had enhanced the income of the Company while finalizing the Company's assessments for the accounting years 1993, 1994-95, 1995-96, 1996-97, six months ended December 31, 1997 and December 31, 1998 (assessment years 1994-95 to 1999-2000), mainly on the contention that the Company has paid excessive amounts for importing certain raw materials. The appeals filed by the Company have been disallowed by the Commissioner of Income Tax Appeals (CITA). The appeals filed by the Company against the order of CITA for the assessment years 1994-95 to 1999-2000 before the Income Tax Appellate Tribunal (ITAT) are still pending. No provision has been made in this respect in the accounts.

26. EARNINGS PER SHARE

There is no dilutive effect on the basic earnings per share of the Company, which is based on:

	2000	1999
	(Rupees in th	ousands)
Profit after taxation	57,824	,
	(Number of	
Weighted average number of Ordinary shares	6,944,760	
	======================================	
Earnings per share - Basic and diluted	8.33	3.18
	(Rupees in th	ousands)
27. CASH GENERATED FROM OPERATIONS	(Rupees in th	ousands)
27. CASH GENERATED FROM OPERATIONS Profit before taxation	(Rupees in th 136,664	nousands) 70,348
		•
Profit before taxation		•
Profit before taxation Adjustment for non cash charges and		•
Profit before taxation Adjustment for non cash charges and other items:	136,664	70,348
Profit before taxation Adjustment for non cash charges and other items: Depreciation	136,664 57,482	70,348 61,290 747
Profit before taxation Adjustment for non cash charges and other items: Depreciation Fixed assets written off - note 9.4	136,664 57,482 53	70,348 61,290 747 (1,370)
Profit before taxation Adjustment for non cash charges and other items: Depreciation Fixed assets written off - note 9.4 Gain on sale of fixed assets	136,664 57,482 53 (1,477)	70,348 61,290 747 (1,370) (1,100)

		15,034
27.1 Working capital changes		
(Increase)/decrease in current assets:		
Stores and spares	568	847
Stock-in-trade		(107,764)
Trade debts		(10,023)
Loans and advances	358	
Deposits and short-term prepayments	109,591	
Other receivables (net)		
(excluding accrued interest)		5,573
	7.402	
(Decrease)/increase in current liabilities:	7,402	(187,080)
Creditors, accrued and other liabilities (net)		
(excluding accruals for financial		
charges and unclaimed dividend)	(48,549)	39,015
		(148,065)
	2000	1999
28. CASH AND CASH EQUIVALENTS	2000 (Rupees in th	
28. CASH AND CASH EQUIVALENTS Cash and cash equivalents comprise of the following items		
28. CASH AND CASH EQUIVALENTS Cash and cash equivalents comprise of the following items as included in the balance sheet:		
Cash and cash equivalents comprise of the following items	(Rupees in th	nousands)
Cash and cash equivalents comprise of the following items as included in the balance sheet: Bank and cash balances		nousands)
Cash and cash equivalents comprise of the following items as included in the balance sheet:	(Rupees in the 4,580 (100,450)	1,527 (158,570)
Cash and cash equivalents comprise of the following items as included in the balance sheet: Bank and cash balances Short-term running finances utilised	(Rupees in the 4,580 (100,450)	1,527 (158,570)
Cash and cash equivalents comprise of the following items as included in the balance sheet: Bank and cash balances Short-term running finances utilised	(Rupees in the 4,580 (100,450)	1,527 (158,570) (157,043)
Cash and cash equivalents comprise of the following items as included in the balance sheet: Bank and cash balances Short-term running finances utilised under mark-up arrangements	4,580 (100,450) (95,870)	1,527 (158,570) (157,043)
Cash and cash equivalents comprise of the following items as included in the balance sheet: Bank and cash balances Short-term running finances utilised under mark-up arrangements 29. TRANSACTIONS WITH ASSOCIATED	4,580 (100,450) (95,870)	1,527 (158,570) (157,043)
Cash and cash equivalents comprise of the following items as included in the balance sheet: Bank and cash balances Short-term running finances utilised under mark-up arrangements 29. TRANSACTIONS WITH ASSOCIATED UNDERTAKINGS	4,580 (100,450)(95,870)	1,527 (158,570)(157,043)
Cash and cash equivalents comprise of the following items as included in the balance sheet: Bank and cash balances Short-term running finances utilised under mark-up arrangements 29. TRANSACTIONS WITH ASSOCIATED UNDERTAKINGS Net sales	4,580 (100,450)(95,870) ====================================	1,527 (158,570)(157,043) ======
Cash and cash equivalents comprise of the following items as included in the balance sheet: Bank and cash balances Short-term running finances utilised under mark-up arrangements 29. TRANSACTIONS WITH ASSOCIATED UNDERTAKINGS Net sales Purchases	4,580 (100,450)(95,870) ====================================	1,527 (158,570)(157,043) ====================================
Cash and cash equivalents comprise of the following items as included in the balance sheet: Bank and cash balances Short-term running finances utilised under mark-up arrangements 29. TRANSACTIONS WITH ASSOCIATED UNDERTAKINGS Net sales	4,580 (100,450)(95,870) ====================================	1,527 (158,570)(157,043) =======
Cash and cash equivalents comprise of the following items as included in the balance sheet: Bank and cash balances Short-term running finances utilised under mark-up arrangements 29. TRANSACTIONS WITH ASSOCIATED UNDERTAKINGS Net sales Purchases Trade discount and commission expenses Other items:	4,580 (100,450)(95,870) ====================================	1,527 (158,570)(157,043) ====================================
Cash and cash equivalents comprise of the following items as included in the balance sheet: Bank and cash balances Short-term running finances utilised under mark-up arrangements 29. TRANSACTIONS WITH ASSOCIATED UNDERTAKINGS Net sales Purchases Trade discount and commission expenses Other items: Recovery of service charges	4,580 (100,450)(95,870) ====================================	1,527 (158,570)(157,043) ====================================
Cash and cash equivalents comprise of the following items as included in the balance sheet: Bank and cash balances Short-term running finances utilised under mark-up arrangements 29. TRANSACTIONS WITH ASSOCIATED UNDERTAKINGS Net sales Purchases Trade discount and commission expenses Other items:	4,580 (100,450)(95,870) ====================================	1,527 (158,570)(157,043) ====================================

30. REMUNERATION OF DIRECTORS AND EXECUTIVES

Royalty and technical fee

The aggregate amounts charged in the accounts for the year for remuneration, including all benefits to the Chief Executive, Working Directors and Executives of the Company were as follows:

	Chief Executive		Directors		Executive		Total	
	2000	1999	2000	1999	2000	1999	2000	1999
	(Rupees in thousands)							
Managerial remuneration	5,984	4,800	4,635	4,202	46,189	38,282	56,808	47,284
Retirement benefits	1,454	1,194	1,123	779	7,836	6,204	10,413	8,177
Perquisites and benefits:								
Rent and utilities	616	1,724	683	1,598	20,888	14,548	22,187	17,870
Medical expenses	82	16	41	47	3,281	1,358	3,404	1,421
Club subscription	726	105	86	81	22	14	834	200
Leave passage	378		295	169	3,022	2,035	3,695	2,204
Income tax paid by								
the Company	1,490	114	1,084				2,574	114

12,838

4,402

	10,730	7,953	7,947	6,876	81,238	62,441	99,915	77,270
	=======================================		==========	=========				
Number	1	1	2	2	172	139	175	142

In addition the Chief Executive, Directors and certain Executives are also provided with free use of the Company's cars.

The above remuneration of Directors does not include amounts paid or provided by the associated undertakings.

Aggregate amount charged in the accounts for fee to two Directors was Rs. One thousand five hundred (1999: Rs. 5 thousand to four Directors).

31. FINANCIAL INSTRUMENTS AND RELATED DISCLOSURES

i) Financial assets and liabilities

	Interest/Mark-up bearing			Non inter	est/Mark-up			
	Maturity upto one year	Maturity after one year	Subtotal	Maturity upto one year	Maturity after one year	Subtotal	Total	Effective Rate of interest %
				(Rupees in	thousands)			
Financial assets								
Trade debts				221,702		221,702	221,702	
Loans to employees	1,962	3,524	5,486				5,486	9-14
Deposits				24,424	2,103	26,527	26,527	
Other receivables				10,913		10,913	10,913	
Bank and cash balances				4,580		4,580	4,580	
	1,962	3,524	5,486	261,619	2,103	263,722	269,208	
Financial liabilities	=======================================	=======================================	=======================================	=======================================	=======================================	=======================================	=======	
Redeemable capital	104,000		104,000				104,000	12.25-13
Short term running								
finances	100,450		100,450	-			100,450	12.5-14
Creditors				269,255		269,255	269,255	
	204,450		204,450	269,255		269,255	473,705	
Off-Balance Sheet Financial Instruments Forward Exchange	=======================================	=======================================						
contracts Guarantees to Banks on				120,797		120,797	120,797	
behalf of employees				43		43	43	

ii) Credit risk

Credit risk represents the accounting loss that would be recognised at the reporting date if counter parties failed to perform as contracted. Out of the total financial assets of Rs 269.208 million, the financial assets which are subject to credit risk amounted to Rs 264.627 million. To manage exposure to credit risk, the Company applies credit limits to its customers.

iii) Currency risk

Currency risk arises where the value of Financial Instrument changes due to change in foreign currency exchange rates. Foreign currency risk arises mainly where receivables and payables exist due to transactions with foreign undertakings, especially group companies. Payables exposed to foreign currency risks are covered through forward foreign exchange contracts.

iv) Liquidity risk

Liquidity risk reflects an enterprise's inability in raising funds to meet commitments. The Company follows an effective cash flow management and planning policy with a one year advance focus to ensure availability of funds and to take appropriate measures for new requirements.

v) Fair values of financial assets and liabilities

The carrying values of all financial assets and liabilities reflected in the financial statements approximate their fair values.

32. CAPACITY AND PRODUCTION

The capacity and production of the Company's manufacturing facility is undeterminable as it is a multiproduct plant involving varying processes of manufacture.

33. CORRESPONDING FIGURES

Previous year's figures have been rearranged and reclassified wherever necessary for the purposes of comparison.

SYED BABAR ALI Chairman M. TARIQ UMAR Chief Executive